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ABSTRACT
Introduction: While opioids have become a
standard treatment option for those
experiencing moderate to severe chronic pain,
side effects of constipation and related
symptoms have interfered with their usage in
as many as 40–50% of treated patients. Prior
research has elucidated the range of these
symptoms, but no study has determined
which of these symptoms patients most desire
improving or whether improving constipation
itself by as little as one more bowel movement
per week is deemed an important change.
Methods: We conducted an online patient
survey of 513 participants residing in one of
six countries who reported having chronic pain,
were taking opioids, and experiencing opioid-
induced constipation (OIC) to address these
questions.
Results: Respondents rank ordered their
preferences and the following eight symptoms
generated [80% endorsement as important to
improve: improvement in having bowel
movements without rectal pain, soft stools
that are not loose or watery, regular bowel
movements, a reduction in rectal straining,
relief from feeling bloated, feeling less fear
about having OIC when following their opioid
medication regime, a desire to worry less overall
about having a bowel movement, and with less
‘stomach’ area pain. When asked ‘how
important is it you to have 1 more bowel
movement per week’’, over 90% endorsed it
was ‘somewhat’, ‘very’, or ‘extremely
important’ with nearly 70% (n = 354)
endorsing the ‘extremely’ or ‘very important’
response options. In multivariate models, being
in more overall pain or reporting fewer than 3
bowel movements per week were found to be
independent predictors of the importance.
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Conclusions: These results highlight the
notable range of OIC symptoms most desired
by patients to improve and demonstrate that
bowel movements of only one more per week
were important to register a meaningful
improvement. The latter is particularly helpful
for those assessing the minimal clinically
important difference in treating this condition.




Over the past 20 years, patients have
increasingly been prescribed long-term courses
of opioids for relief of their chronic
musculoskeletal or cancer pain [1]. While the
central nervous system effects of these drugs
have clearly helped ease the painful discomfort
and improve quality of life for those afflicted,
off-target side effects on the gastrointestinal
tract are noted in as many as 40–50% of these
patients [2–7]. These side effects are
predominantly a very noticeable and
unrelenting chronic constipation, the so-called
opioid-induced constipation (OIC), which
occurs within the first weeks of opioid
treatment. To date, OIC is largely addressed by
lifestyle modification in terms of increasing
dietary fiber, rotating courses of therapy with
alternative opioids or by taking concomitant
laxatives or stool softeners [8]. Despite these
approaches, nearly 50% of OIC patients do not
improve and for many, their symptoms are
bothersome enough to lead to lowering or even
skipping their opioid doses to improve their
debilitating constipation [9].
A variety of studies have sought to
characterize the patient experience of both the
nature of OIC-related discomfort and its impact
on activities of daily living and ensuing quality
of life. The symptoms of OIC frequently cited
include having fewer than three bowel
movements per week, bloating, cramping,
infrequent passage of hard stools, straining,
spasms, flatulence, hard and dry stools,
nausea, vomiting, abdominal pain and reflux
[2, 4, 8, 10–12]. The impact of these symptoms
has been shown to lead to impairment in the
activities of daily living and work productivity
[13, 14].
While it is clear that the hallmark of OIC is
to experience infrequent bowel movements, it
is not clear from prior patient research [10, 11]
which of all the myriad OIC symptoms
previously studied are the most important
ones that patients would prefer to improve
upon. Additionally, there is a lack of prior
research to determine the effect size or degree
of improvement patients are seeking in terms of
increasing the number of bowel movements
they experience per week due to OIC. The
purpose of the present study was therefore to
survey OIC patients to identify which of their
many symptoms were viewed as those most
important to be improved upon. We also sought
to establish whether an increase of one more
bowel movement per week was deemed
sufficient to make a difference to patients
suffering from OIC.
METHODS
The study was designed as a cross-sectional,
geographically dispersed online self-reported
survey of patients experiencing OIC. Questions
were designed with responses to be both
categorical, using various scales, and also
incorporate open-ended text to fully elucidate
the nuances of the impact of OIC on patients’
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lives. The results from the free-text or
qualitative responses are the subject of a
separate paper.
Study participants were drawn from a large
online patient database of over 800,000
individuals, and sampled within the following
six countries: US, UK, Canada, Germany,
Sweden and Norway. Participants were
screened via e-mail and if they met the
inclusion criteria, they were invited to
participate in an online survey. The inclusion
criteria were defined by each respondent
meeting all of the following: minimum
18 years of age; self-reporting of chronic non-
cancer pain; noting at least two active
symptoms of OIC; taking a chronic course of
opioid medications; confirming an ability to
read or speak the language of the country the
survey was administered; and a willingness and
ability to provide written consent for
participation.
The target sample size for the convenience
sample was 500 respondents indicating they
had OIC. Surveys were collected in May 2014
via a secured, online web-based survey system
(HealthiVibe, LLC, Arlington, VA, USA). To do
so, eligible participants were directed to a secure
URL to access the survey that comprised a series
of multiple-choice, closed-ended and free-text
questions, which took approximately
12–15 min to complete.
The primary objectives of interest were to
determine those symptoms of OIC that most
patients ([80%) would prefer to improve, and
to determine whether one more bowel
movement per week was considered
‘extremely’ or ‘very’ important to them, as
phrased in the question: ‘‘How important is it
to you to have one more bowel movement per
week?’’ Pre-planned additional analyses were
envisioned to determine which various
potential patient subgroups were more or less
likely to endorse this degree of symptomatic
improvement.
Specific opioid drugs used by respondents
were later dichotomized into a categorical
variable with pharmacologically weak vs.
strong opioids as follows: weak (tramadol,
hydrocodone, codeine, dihydrocodeine) or
strong (morphine, oxycodone, fentanyl,
hydromorphone, methadone).
Statistical Analysis
Chi-square tests were used to assess bivariate
associations for categorical variables. t tests
assuming non-equal variance were used to
evaluate differences for bivariate continuous
variables. Logistic regression models were used
to assess factors associated with participants
agreeing that one more bowel movement per
week was sufficient to be ‘extremely’ or ‘very’
important to them (vs. those stating it was only
‘somewhat’ or ‘not’ important). The regression
model included participant age, gender,
reporting of strong vs. weak opioid usage,
severity of chronic pain on a scale of 0–10 (with
increasing pain represented by increasing score),
presence or absence of neuropathic pain, having
fewer or more than three spontaneous bowel
movements per week, and place of residence
being a European or North American locale.
Odds ratios were estimated to measure strengths
of association and 95% confidence limits were
estimated to assess precision. A P value\0.05 was
used to determine statistical significance. All
analyses were performed using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA).
Compliance with Ethics Guidelines
This article does not contain any new
experimental studies with human or animal
subjects performed by any of the authors.
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RESULTS
As noted in Table 1, a total of 513 participants
engaged in providing their input in the online
survey. They were, on average, 46 years of age,
with 55% female, 88.5% Caucasian, and most
having at least high school education. There were
approximately 100 (20%) participants from each
of the following countries: US, Canada, Germany
and the UK.The combined participation rate from
the Nordic countries comprised 72 participants or
14.1% of the total sample. Very few participants
(11%) self-reported being in either ‘excellent’ or
‘very good’ health (Table 2). Participants could list
multiple reasons for their chronic pain, with more
than two-thirds indicating they had either back or
musculoskeletal pain. Their average degree of
pain on a 0–10 scale was 6.7, and they reported
having their pain for a mean of 10.6 years.
A little more than half reported taking
pharmacologically strong opioids, while slightly
fewer than half reported taking weaker opioids.
The improvements that more than 80% of
participants with OIC would prefer to see are to
have bowel movements without pain, soft
stools that are not loose or watery, a reduction
in rectal straining, and relief from feeling
bloated (see Table 3). Additionally, more than
80% of participants with OIC would prefer to
feel less fear about having OIC when they
followed their opioid medication regime,
worry less overall about having a bowel
movement, and have less ‘stomach’ area pain.
79.3% of participants also stated they would
prefer to avoid taking laxatives or suppositories
to help with their constipation.
Being able to have a bowel movement on a
‘regular’ basis was considered an important
symptom to improve upon by more than 86%
of the respondents. When asked, ‘‘How
important is it for you to have one more bowel
movement per week?’’ over 90% responded that
it was ‘somewhat’, ‘very’, or ‘extremely’
important, with over 70% (n = 354) supporting
the ‘extremely’ or ‘very’ important response
options (Table 4). Respondents from the Nordic
countries appeared to vary slightly in their
response to this question compared with
respondents from other countries in that 48%
(Norway) and 57% (Sweden) considered one
more bowel movement per week as being ‘very’
or ‘extremely’ important, compared with
70–83% of respondents from the other
countries surveyed. Overall, only 3.9% of
respondents felt that having one more bowel
movement would not be an important difference
representing an improvement in their condition.
The remaining 4.3% of respondents indicated
that they did not know whether one more bowel
movement per week would make a difference to
them and were not included in the table.
Nearly, 60% of respondents noted that they
took less of their pain medication when they
were constipated: 10% stated they ‘always’ took
Table 1 Baseline characteristics of participants
Characteristic Participants
(n5 513)
Mean (SD) age, years 46.1 (13.0)
Female, n (%) 282 (55)







Caucasian, n (%) 454 (88.5)
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less pain medication while constipated, while
an additional 19% stated they ‘usually’ took less
pain medication; 30% stated they ‘sometimes’
took less.
Table 5 shows a comparison of some of the
categorical factors evaluated for their
association with the participants’ response that
having one more bowel movement per week
was important. Numerically, more than 70% of
younger adults (\65 years) felt that having one
more bowel movement per week was
‘extremely’ or ‘very’ important compared with
56% of those aged C65 years, though these
differences were not statistically significant (it
should be noted, however, that the sample size
of those C65 years was small). As might be
expected, more participants who had either
fewer than three bowel movements per week
or were in more severe pain endorsed the
importance of having one more bowel
movement per week.
Figure 1 displays the box-and-whisker plot of
results from the logistic regression equation to
examine which of the factors were
independently related to endorsing the
importance of experiencing a single additional
bowel movement per week. Again, being in
more overall pain or reporting fewer than three
bowel movements per week were found to be
independent predictors, while age, gender,
pharmacological strength of opioid taken, and
geography of residence were not found to be
predictors.
DISCUSSION
Many studies have sought to understand the
range of symptoms experienced by people
living with OIC, though none have been
designed to understand patients’ specific
preferences for which aspects are most
important to improve. In our study, we found
that more than 80% of 513 participants across
six countries endorsed seeking an improvement
in eight particular areas of concern that ranged
from having regular bowel movements to
assuaging fear and worry related to their
condition. For individuals involved with the
clinical monitoring of patients with OIC to
detect an improvement in constipation, a
specific focus on these symptoms seems
warranted.
It is interesting that most patients in our
study viewed having one more bowel
Table 2 Clinical characteristics of participants
Characteristics Participants
(n5 513)
Self-rating of health, n (%)
Excellent 13 (2.5)




Reason for pain, n (%)
Back pain 409 (79.7)
Fibromyalgia 104 (20.3)
Headache 254 (49.5)
Joint pain 358 (69.8)
Nerve damage 144 (28.1)
Osteoarthritis 145 (28.3)
Pain syndrome 106 (20.7)
Rheumatoid arthritis 119 (23.2)
Mean (SD) rating of pain
(in the past week) on a 0–10 scale
6.7 (1.6)
Mean (SD) duration of pain, years 10.6 (9.5)
Participants taking opioids by type, n (%)
Strong opioids 298 (58.1)
Weak opioids 215 (41.9)
SD Standard deviation
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movement per week as ‘extremely’ or ‘very’
important. This is a very telling finding in that
even a seemingly small change was not deemed
small to these patients. Clearly, the impact of
OIC is important to these patients and a change
is desired. While the study did not have
sufficient statistical power to find a difference,
numerically, those participants who were
younger than 65 years of age appeared to be
even more sensitive to this level of
improvement. It is not surprising, as others
have noted that OIC can adversely affect both
workplace productivity and activities of daily
living [10], and those under the age of 65 are
particularly vulnerable to either issue.
Our study noted a high proportion (60%) of
patients who responded that they reduced their
pain medication as a result of their
constipation. Prior research with interviewer-
administrated questionnaires, as opposed to our
anonymized online survey, may result in social
desirability response bias [15], where the
respondent seeks to please the interviewer and
not provide responses that are counter to the
interviewer’s desire. Patient responses admitting
to a self-initiated reduction in prescribed
medication is not easy for patients. Therefore,
our use of an anonymized online survey may
have allowed a more honest response to this
question leading to a seemingly high response
confirming that patients reduced their pain
medication.
It was noticeable that participants in our
study who had chronic pain and were taking
opioids experienced OIC scores much lower on
the frequently utilized epidemiologic question
asking patients to self-rate their overall general
health. In a recent evaluation of the US
National Health and Nutritious Examination
Survey (NHANES) data, 17% of a representative
sample of US residents reported their health as
‘excellent’ and 32% reported it as ‘very good’
[16]. In our study, only 2.5% of respondents
reported their health as ‘excellent’ with 8.9%
reporting being in ‘very good’ health.
Interestingly, a recently published study of
similarly defined OIC participants found that
only 1.4% of participants reported their health
Table 3 Aspects of constipation most (C80%)
participants would prefer to improve
Aspect Participants in
agreement, %
Be able to have a bowel movement
without pain
87.9
Be able to have a soft stool that is not
loose or watery
87.1
Not experience rectal straining due to
my constipation
83.4
Feel less bloated 83.0
Be more comfortable using my opioid
medication without fear of being
constipated
82.1
Worry less about being able to have a
bowel movement
80.5
Have less pain in my stomach area 80.3
Table 4 Participants who considered that C1 more bowel
movement per week was an important change












a Respondents endorsed this change as ‘somewhat’, ‘very’
or ‘extremely’ important
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Table 5 Bivariate analyses of selected patient factors in relation to the belief that one more bowel movement per week
would make an important difference in OIC symptoms
Factor Response (%) to the question, ‘‘How important is it to you to have one more bowel movement per
week?’’
Extremely Very Somewhat Not P value
Age, years
\65 (n = 468) 37.2 33.1% 21.6 3.9
C65 (n = 45) 26.7 28.9 35.6 4.4 0.2841
Weekly number of bowel movements
\3 (n = 225) 40.9 35.6 18.7 1.3
C3 (n = 288) 32.6 30.6 26.0 5.9 0.0086
Mean pain score in the past week on a scale of 0–10
B7 (n = 369) 32.5 33.1 26.0 4.3
[7 (n = 144) 45.8 31.9 14.6 2.8 0.0186
Percentages may not sum to 100% as some participants indicated ‘don’t know’ and are not depicted here. A response of
‘don’t know’ did not exceed[5%
Fig. 1 Factors independently related to the response that
having one more bowel movement per week was ‘extremely’
or ‘very’ important vs. all other responders. PAIN_SCALE
refers to the numeric 0–10 response to the pain severity
question; SBM_LT3 refers to whether the patient had
fewer than 3 spontaneous bowel movements per week
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as ‘excellent’ and 6.7% as ‘very good’; very close
to our findings [10]. We were not able to study
the contribution of constipation to the
diminished self-rated responses to general
health perception, but it would be useful for
future researchers to consider determining the
degree to which the underlying physical reason
for pain, the use of opioids, and/or the side
effects of OIC contribute to these overall low
ratings.
A potential limitation of our study was the
way in which we drew our study sample from an
online patient database. This could bias in favor
of reflecting the preferences of a higher
socioeconomic background than the average
person with OIC. By definition, our participants
had to be internet-savvy, and able and willing
to participate in a web-based study. The fact that
[90% of our participants had completed at least
high school education reflects their potentially
high socioeconomic status. Yet, the
demographic, clinical characteristics and
overall health of our participants were very
similar to those noted in a recently published
study whose participants were drawn from
primary care clinics, pain management clinics
and clinical research sites across some of the
same countries we studied (US, Canada,
Germany, UK) [10]. So while it may be that
our participants were better educated, it does
appear that they are otherwise similar to those
OIC patients identified by other means.
Another limitation of our study was the lack
of daily dosages of pain medications. However,
we were able to obtain the name of the specific
opioid and later stratified them into strong or
weak opioids. The addition of daily dosage
could have refined our analyses further.
Our study enrolled a relatively small sample
size of older respondents. Our analysis of age in
relation to the impact of OIC suggests that the
problems and desired solutions were more
pronounced among younger (\65 years) than
older (C65 years) respondents. Future research
should seek to enroll a wider age range to tease
out the influence of age on desired health state.
CONCLUSIONS
Our study is the first to identify which of many
OIC symptoms are most important to detect
clinically meaningful improvement from a
patient perspective. Additionally, we found
that over 90% of patients reported that one
more bowel movement per week was considered
an important improvement in this overall
problem, which is associated with chronic
opioid usage. This degree of improvement may
serve as an effect size or minimal clinically
important difference for future research studies
that seek to improve the condition of patients
suffering from OIC.
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